Compare General Dynamics Corporation (GD) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Dynamics Corporation vs Inovio Pharmaceuticals Inc — how do they compare? General Dynamics Corporation trades at $391.47 (market cap $106.03B), while Inovio Pharmaceuticals Inc trades at $0.75 (market cap $78.55M). The key difference: General Dynamics Corporation is far larger — about 1349.8× Inovio Pharmaceuticals Inc's market cap, and General Dynamics Corporation pays a 1.62% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| GD | INO | |
|---|---|---|
Market Cap | $106.03B | $78.55M |
Sector | Industrials | Health |
52-Week High | $395.97 | $2.87 |
52-Week Low | $312.53 | $0.66 |
Enterprise Value | $111.17B | $49.56M |
Dividend Yield | 1.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Dynamics (GD) trades at $395.97, up 1.0% on the day, near its 52-week high. The stock shows bullish technical momentum with consistent earnings beats, including Q2 2026 EPS of $4.24 versus $3.96 expected. Revenue growth is robust, with 2025 revenue at $52.55 billion, and the company secured a major $76.6 billion Navy contract in July 2026, boosting its backlog.
Outlook remains positive driven by defense budget tailwinds and strong contract wins, but valuation multiples like a P/E of 23.9 suggest limited upside from current levels. Risks include execution on large contracts and macroeconomic pressures on government spending.
INO shares trade at $0.74, up 10.24% today, but remain significantly below analyst consensus targets. The biotech firm shows improving operational trends with three consecutive quarterly earnings beats, though financials reveal substantial losses with -130% net margin. Technical indicators signal bearish momentum despite neutral oscillators. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with the company recently raising $20 million to fund operations.
Outlook hinges on FDA approval of INO-3107, representing a binary event that could drive substantial upside given the $3.25 consensus target. However, persistent cash burn, negative profitability metrics, and ongoing shareholder litigation pose significant risks. The stock offers high-risk, event-driven potential for speculative investors willing to accept regulatory and financial uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
